Pharmacotherapy of neuroendocrine tumors
- Authors: Emelyanova G.S.1, Orel N.F2, Odintsova A.S1, Gorbunova V.A1
-
Affiliations:
- N.N. Blokhin National Medical Research Center of Oncology
- Russian Medical Academy of Continuous Professional Education
- Issue: No 12 (2018)
- Pages: 76-80
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/295830
- DOI: https://doi.org/10.18565/pharmateca.2018.12.76-80
- ID: 295830
Cite item
Open Access
Access granted
Abstract
The choice of therapy for the treatment of neuroendocrine tumors (NETs) depends on the location, morphological and functional features. The main algorithms and treatment approaches were published in the ENETS 2016 clinical guidelines. Somatostatin analogues (lanreotide and octreotide) are the 1st-ine therapy for high-differentiated tumors, while chemotherapy is the standard of care for poorly differentiated NETs. Targeted therapy is prescribed for progressive high-differentiated NETs. Timely diagnosis and an individualized approach to treatment remain the main condition for effective treatment.
Full Text
About the authors
Galina S. Emelyanova
N.N. Blokhin National Medical Research Center of Oncology
Email: docgalina@mail.ru
PhD
N. F Orel
Russian Medical Academy of Continuous Professional Education
A. S Odintsova
N.N. Blokhin National Medical Research Center of Oncology
V. A Gorbunova
N.N. Blokhin National Medical Research Center of Oncology
References
- Reisine T., Bell G. Molecular biology of somatostatin receptors. Endocr. Rev. 1995;16:427-42.
- Susini C., Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann. Oncol. 2006;17(12):1733-42.
- Kvols L.K. Metastatic carcinoid tumors and the malignant carcinoid syndrome. Ann. N.Y. Acad. Sci. 1994;15(733):464-70.
- Eriksson B., Klöppel G., Krenning E., et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumors-welldifferentiated jejunal-ileal tumor/carcinoma. Neuroendocrinol. 2008;87:8-19.
- Ruszniewski P., Ish-Shalom S., Wymenga M., et al. Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide. Neuroendocrinol. 2004; 80(4):244-51.
- Strosberg J.R., Benson A.B., Huynh L., et al. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study. Oncologist. 2014;19(9):930-36.
- Al-Efraij K., Aljama M.A., Kennecke H.F. Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors. Cancer Med. 2015;4(6):864-70. doi: 10.1002/cam4.435.
- Rinke A., Müller H.H., Schade-Brittinger C., et al. PROMiD Study Group. Placebocontrolled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMiD Study Group. J. Clin. Oncol. 2009;27(28):4656-63. doi: 10.1200/JCO.2009.22.8510.
- Caplin M.E., Pavel M., Cwikfa J.B., et al.; CLARINET investigators. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N. Engl. J. Med. 2014;371(3):224-33. Doi: 10.1056/ NEJMoa1316158.
- Aparicio-Pages M.N., Verspaget H.W., Pena A.S., et al. Natural killer cell activity in patients with neuroendocrine tumours of the gastrointestinal tract; relation with circulating gastrointestinal hormones. Neuropeptides. 1991;20(1):1-7.
- Oberg K. Interferon in the management of neuroendocrine GEP_tumors. Digest. 2000;62(Suppl. 1):92-7.
- Oberg K. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours. Ann. Oncol. 2001;12(Suppl. 2):111-14.
- Oberg K. Interferon-alpha versus somatostatin or the combination of both in gastroenteropancreatic tumours. Digestion. 1996;57(Suppl. 1):81-3.
- Raymond E., Dahou L., Raoul J.L., et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 2011;364(6):501-13.
- Pavel M., O'Toole D., Costa F., et al. Consensus Guidelines update for the management of distant mrtastatic disease of intestinal, pancreartic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neurooncology. 2016;03(2):172-85.
- Yao J., Shah M., Ito T., et al. RAD 001 in advanced Neuroendocrine Tumors, Third Trial (RADIANT -3) Study Groupe. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 2011;364(6):514-23.
- Bajetta E., Catena L., Fazio N., et al. Everolimus in combination with octreotide longacting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study. Cancer. 2014;120(16): 2457-63.
- Caplin M., Baudin E., Ferolla P., et al. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann. Oncol. 2015;26:1604-20.
Supplementary files
